The evolution of aldosterone antagonists

被引:122
作者
Garthwaite, SM [1 ]
McMahon, EG [1 ]
机构
[1] Pfizer Inc, Global Project Managament, Skokie, IL USA
关键词
aldosterone; spironolactone; eplerenone; aldosterone blockers; aldosterone antagonists; selectivity;
D O I
10.1016/j.mce.2003.10.005
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Since the isolation and purification of aldosterone from adrenal extracts 50 years ago (Experientia 9 (1953) 33), scientists have learned a great deal about how and where aldosterone acts, the factors that control its release, what is its role in the pathophysiology of cardiovascular disease. how to make and study aldosterone antagonists, and for what medical purposes these agents are useful. In this paper, we will discuss the evolution of aldosterone antagonists from the relatively nonselective spironolactone (Aldactone(R)), to the highly selective eplerenone (Inspra(R)). Eplerenone represents a molecule with improved steroid receptor selectivity and pharmacokinetic properties ill man compared to spironolactone. Recent clinical results have demonstrated that these improvements translate into tolerability and efficacy in patients with cardiovascular disease. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:27 / 31
页数:5
相关论文
共 50 条
  • [31] The Effect of Aldosterone Antagonists for Ventricular Arrhythmia: A Meta-Analysis
    Wei, Jiafu
    Ni, Juan
    Huang, Dejia
    Chen, Mao
    Yan, Shaodi
    Peng, Yong
    CLINICAL CARDIOLOGY, 2010, 33 (09) : 572 - 577
  • [32] Antagonists of aldosterone and proteinuria in patients with CKD: An uncontrolled pilot study
    Bianchi, S
    Bigazzi, R
    Campese, VM
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (01) : 45 - 51
  • [33] Aldosterone breakthrough during ras blockade: A role for endothelins and their antagonists?
    Gian Paolo Rossi
    Current Hypertension Reports, 2006, 8 : 262 - 268
  • [34] The role of aldosterone receptor antagonists in the management of heart failure: An update
    Nagarajan, Vijaiganesh
    Chamsi-Pasha, Mohammed
    Tang, W. H. Wilson
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2012, 79 (09) : 631 - 639
  • [35] Aldosterone Antagonists in Patients With Heart Failure
    Ghali, Jalal K.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (09): : 833 - 834
  • [36] Aldosterone antagonists in systolic heart failure
    Lindblad, Adrienne J.
    Allan, G. Michael
    CANADIAN FAMILY PHYSICIAN, 2014, 60 (02) : E104 - E104
  • [37] Use of Aldosterone Antagonists in Heart Failure
    Albert, Nancy M.
    Yancy, Clyde W.
    Liang, Li
    Zhao, Xin
    Hernandez, Adrian F.
    Peterson, Eric D.
    Cannon, Christopher P.
    Fonarow, Gregg C.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (15): : 1658 - 1665
  • [38] Treatment Considerations With Aldosterone Receptor Antagonists
    Sica, Domenic A.
    Flack, John M.
    JOURNAL OF CLINICAL HYPERTENSION, 2011, 13 (01) : 65 - 69
  • [39] Evolution of mineralocorticoid receptor antagonists, aldosterone synthase inhibitors, and alternative treatments for managing primary aldosteronism
    Yoshida, Yuichi
    Shibata, Hirotaka
    HYPERTENSION RESEARCH, 2025, 48 (02) : 854 - 861
  • [40] The role of aldosterone in kidney diseases and hypertension. Is it worth using mineralocorticoid receptor antagonists in clinical practice?
    Donderski, Rafal
    Manitius, Jacek
    ARTERIAL HYPERTENSION, 2019, 23 (01): : 1 - 7